Cellectar Biosciences (CLRB) Income from Continuing Operations (2010 - 2026)
Cellectar Biosciences (CLRB) posted Income from Continuing Operations of 5845629.0 for Q4 2025, down 16.76% sequentially from 5006696.0 in Q3 2025, and up 95.14% YoY from 2995639.17 in Q4 2024.
Cellectar Biosciences (CLRB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Income from Continuing Operations for 16 years, with the latest figure at 5845629.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 95.14% year-over-year to 5845629.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 24030845.0 (up 85.12% YoY) and the FY2025 annual result came in at 21669037.0, up 38.37% from the prior year.
- Income from Continuing Operations slipped to 5845629.0 in Q4 2025 per CLRB's latest filing, from 5006696.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 5006696.0 in Q3 2025 and troughed at 120229826.0 in Q4 2024.
- A 5-year average of 17701077.8 and a median of 7733005.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations tumbled 1205.38% in 2022, then surged 95.14% in 2025.
- Over 5 years, Income from Continuing Operations stood at 6154991.0 in 2021, then sank by 1205.38% to 80345901.0 in 2022, then soared by 82.29% to 14230546.0 in 2023, then slumped by 744.87% to 120229826.0 in 2024, then soared by 95.14% to 5845629.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 5845629.0, 5006696.0, and 6621529.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - | -7.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.34 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -6.56 Mn |
| Dec 31, 2024 | -120.23 Mn |
| Sep 30, 2024 | -14.02 Mn |
| Jun 30, 2024 | -14.43 Mn |
| Mar 31, 2024 | -12.77 Mn |
| Dec 31, 2023 | -14.23 Mn |
| Sep 30, 2023 | -9.67 Mn |
| Jun 30, 2023 | -8.57 Mn |
| Mar 31, 2023 | -8.85 Mn |
| Dec 31, 2022 | -80.35 Mn |
| Sep 30, 2022 | -8.03 Mn |
| Jun 30, 2022 | -7.44 Mn |
| Mar 31, 2022 | -6.14 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -6.19 Mn |
| Jun 30, 2021 | -6.44 Mn |